Cronos surges past $0.27 after big partnerships, but BlockchainFX’s $0.021 presale with 90% APY, $500K giveaway, and 35% bonus could be the next 100x crypto.Cronos surges past $0.27 after big partnerships, but BlockchainFX’s $0.021 presale with 90% APY, $500K giveaway, and 35% bonus could be the next 100x crypto.

Crypto Market Trends: Cronos Price Hits $0.27 While BlockchainFX Presale Emerges as the Best Token to Invest Now

markett bitcoin

Have you ever looked back at a missed crypto ICO and thought—that could have been life-changaing? Cronos recently spiked after high-profile partnerships, leaving many wishing they had bought earlier. But while that ship has already sailed, BlockchainFX ($BFX) is handing out a rare second chance. This is not just another crypto presale launching soon—it’s an early access crypto presale with explosive presale momentum, real revenue, and life-changing upside. With its bonus code AUG35 giving 35% more tokens before August ends, the window to join is closing fast.

image 32

Use AUG35 now and grab 35% more $BFX before August ends—don’t miss your second chance.

BlockchainFX ($BFX) Presale Ignites With Explosive Growth and 90% APY Rewards

BlockchainFX isn’t a promise. It’s already live, CertiK-audited, revenue-generating, and attracting over 10,000 daily users. The app unites crypto, stocks, forex, and commodities into one super app—while paying out up to 70% of trading fees daily in USDT rewards. Early buyers are earning 4–7% per day, with annualized returns hitting 90% APY.

The presale price jumped from $0.02 to $0.021, with more than $6.28M raised from 6,786+ participants. A confirmed $0.05 launch price means participants are guaranteed a minimum 2.3x gain before listing. Forecasts place $BFX between $0.10–$0.25 in 2025, with long-term projections above $1 as adoption scales.

Missed Ethereum’s $0.31 ICO? Skipped Solana’s $0.22 entry? BlockchainFX is your second chance at the next 100x crypto presale. Add in a $500,000 giveaway celebrating its launch, plus the exclusive Founder’s Club tiers with Visa cards, NFT perks, and staking bonuses, and the opportunity becomes undeniable.

image 30

🔥 Act today—use AUG35 for 35% extra tokens before August ends.

Cronos Price Action Triggers Regret While BFX Still Offers Early Entry

Cronos (CRO) has been dominating crypto news. After striking a deal tied to Trump Media’s CRO Strategy, Cronos surged over 42% in 24 hours, pushing its price toward $0.27–$0.36 with market cap climbing above $9B. Institutional backing and rapid trading volume expansion sent shockwaves through the crypto market, proving once again how early entries create millionaire-making potential.

But here’s the regret trigger: Cronos’ ICO moment is gone. Anyone who hesitated missed its meteoric run. BlockchainFX, however, is still at presale stage—today’s buyers are at the ground floor before public listing. It’s not just a trending presale crypto; it’s the best token presale 2025 with explosive presale upside still live.

image 1 5

Comparison Table: Why BlockchainFX Beats the Market

CoinLaunch YearICO / Presale PricePredicted Price (2025)Long-Term TargetCurrent Success
BFX2025$0.021$0.10 – $0.25> $1$6.28M raised, 90% APY rewards, 6,786+ buyers, $500K giveaway
Cronos (CRO)2021$0.30 – $0.40~$1+42% daily surge, >$9B market cap, institutional backing

⚡ Join the BFX presale now—your second chance at a 1000x potential crypto.

Conclusion: Last Chance Before Public Listing—Don’t Repeat Past Regrets

The story is simple: Cronos already rewarded its early buyers. BlockchainFX is offering that same door of opportunity right now. With a confirmed $0.05 launch price, 90% APY rewards, a $500K giveaway, and 35% bonus tokens via AUG35, it’s the urgent token presale to join before summer ends. This is the best token to invest now, the top crypto presale today, and your chance to catch the millionaire-making potential crypto before it leaves presale forever.

🚨 Use AUG35 now and claim 35% more $BFX tokens before August closes. Don’t look back in regret.

Find Out More Information Here

Website: https://blockchainfx.com/ 

X: https://x.com/BlockchainFXcom

Telegram Chat: https://t.me/blockchainfx_chat

This article is not intended as financial advice. Educational purposes only.

Market Opportunity
TokenFi Logo
TokenFi Price(TOKEN)
$0.004691
$0.004691$0.004691
-4.69%
USD
TokenFi (TOKEN) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Edges higher ahead of BoC-Fed policy outcome

Edges higher ahead of BoC-Fed policy outcome

The post Edges higher ahead of BoC-Fed policy outcome appeared on BitcoinEthereumNews.com. USD/CAD gains marginally to near 1.3760 ahead of monetary policy announcements by the Fed and the BoC. Both the Fed and the BoC are expected to lower interest rates. USD/CAD forms a Head and Shoulder chart pattern. The USD/CAD pair ticks up to near 1.3760 during the late European session on Wednesday. The Loonie pair gains marginally ahead of monetary policy outcomes by the Bank of Canada (BoC) and the Federal Reserve (Fed) during New York trading hours. Both the BoC and the Fed are expected to cut interest rates amid mounting labor market conditions in their respective economies. Inflationary pressures in the Canadian economy have cooled down, emerging as another reason behind the BoC’s dovish expectations. However, the Fed is expected to start the monetary-easing campaign despite the United States (US) inflation remaining higher. Investors will closely monitor press conferences from both Fed Chair Jerome Powell and BoC Governor Tiff Macklem to get cues about whether there will be more interest rate cuts in the remainder of the year. According to analysts from Barclays, the Fed’s latest median projections for interest rates are likely to call for three interest rate cuts by 2025. Ahead of the Fed’s monetary policy, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, holds onto Tuesday’s losses near 96.60. USD/CAD forms a Head and Shoulder chart pattern, which indicates a bearish reversal. The neckline of the above-mentioned chart pattern is plotted near 1.3715. The near-term trend of the pair remains bearish as it stays below the 20-day Exponential Moving Average (EMA), which trades around 1.3800. The 14-day Relative Strength Index (RSI) slides to near 40.00. A fresh bearish momentum would emerge if the RSI falls below that level. Going forward, the asset could slide towards the round level of…
Share
BitcoinEthereumNews2025/09/18 01:23